Tandem Autologous/Reduced-Intensity Conditioning Allogeneic Stem-Cell Transplantation Versus Autologous Transplantation in Myeloma: Long-Term Follow-Up
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Purpose: Results of allogeneic stem-cell transplantation (allo) in myeloma are controversial. In this trial autologous stem-cell transplantation (auto) followed by reduced-intensity conditioning matched sibling donor allo (auto-allo) was compared with auto only in previously untreated multiple myeloma. Patients and Methods: In all, 357 patients with myeloma up to age 69 years were enrolled from 2001 to 2005. Patients with an HLA-identical sibling donor were allocated to the auto-allo arm (n = 108) and patients without a matched sibling donor were allocated to the auto arm (n = 249). Single (n = 145) or tandem (n = 104) auto was optional. Conditioning for the auto arm was melphalan 200 mg/m 2 ; conditioning for the allo arm was total-body irradiation 2 Gy plus fludarabine 30 mg/m 2 /d for 3 days. Median follow-up time was 61 months. Primary end point was progression-free survival. Results: Progression-free survival at 60 months was significantly better with auto-allo than with allo alone (35% v 18%; P = .001), as was the risk of death and of relapse in the long term (P = .047 and P = .003, respectively). Overall survival at 60 months was 65% versus 58%, and relapse incidence was 49% versus 78%. Complete remission rates were 51% and 41%, respectively (P = .020). Nonrelapse mortality at 24 months was 12% after auto-allo compared with 3% in the auto group (P < .001). The incidence of grade 2 to 4 acute graft-versus-host disease (GvHD) was 20%, and the incidence of limited and extensive chronic GvHD was 31% and 23%. Conclusion: In patients with previously untreated multiple myeloma, long-term outcome with respect to progression-free survival, overall survival, and relapse rate is superior after auto-allo compared with auto only. Nonrelapse mortality is at a reasonable level in both groups.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S. E., Hawkins, K., Brown, J., Drayson, M. T., & Selby, P. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022340 · Cited by 1,768 · cited 1×
“HDT with autologous stem-cell transplantation (ASCT) is part of the first-line standard treatment in patients up to the age of 65 years on the basis of the results of randomized trials.(3,4) Allogeneic stem-cell transplantation (alloSCT) with myeloablative conditioning has been used in myeloma since the mid1980s,(5) b…”
BackgroundA Comparison of Allografting with Autografting for Newly Diagnosed Myeloma
Bruno, B., Rotta, M., Patriarca, F., Mordini, N., Allione, B., Carnevale-Schianca, F., Giaccone, L., Sorasio, R., Omedè, P., Baldi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065464 · Cited by 501
Cited by
Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
Kumar, S. K., Callander, N. S., Alsina, M., Atanackovic, D., Biermann, J. S., Chandler, J. C., Costello, C., Faiman, M., Fung, H. C., Gasparetto, C., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0023 · Cited by 279
Krishnan, A., Pasquini, M. C., Logan, B., Stadtmauer, E. A., Vesole, D. H., Alyea, E., Antin, J. H., Comenzo, R., Goodman, S., Hari, P., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70243-1 · Cited by 274
Management of relapsed multiple myeloma: Recommendations of the International Myeloma Working Group
Laubach, J., Garderet, L., Mahindra, A., Gahrton, G., Caers, J., Sezer, O., Voorhees, P., Leleu, X., Johnsen, H. E., Streetly, M., et al. (2016) · Leukemia · doi:10.1038/leu.2015.356 · Cited by 258
Self-citation
Metadata
- Authors
- Björkstrand, B., Iacobelli, S., Hegenbart, U., Gruber, A., Greinix, H., Volin, L., Narni, F., Musto, P., Beksac, M., Bosi, A., Milone, G., Corradini, P., Goldschmidt, H., de Witte, T., Morris, C., Niederwieser, D., & Gahrton, G.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-08-01
- Volume
- 29
- Issue
- 22
- Pages
- 3016-3022
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2159773146
- Cited by
- 182
- References
- 3
- FWCI
- 12.26
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.